2,411,093 Shares in Savara Inc. $SVRA Acquired by Spruce Street Capital LP

Spruce Street Capital LP purchased a new position in shares of Savara Inc. (NASDAQ:SVRA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,411,093 shares of the company’s stock, valued at approximately $14,539,000. Savara makes up 4.8% of Spruce Street Capital LP’s portfolio, making the stock its 8th largest position. Spruce Street Capital LP owned about 1.18% of Savara as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new stake in Savara in the second quarter valued at approximately $30,000. BNP Paribas Financial Markets grew its stake in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new stake in Savara during the second quarter worth approximately $33,000. Russell Investments Group Ltd. increased its stake in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after purchasing an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Savara in the third quarter valued at $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Savara stock opened at $5.33 on Tuesday. The firm’s 50 day simple moving average is $5.28 and its 200 day simple moving average is $5.60. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.09 billion, a PE ratio of -9.52 and a beta of 0.26. Savara Inc. has a 1-year low of $1.98 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, analysts expect that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Oppenheimer started coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. William Blair set a $10.00 price target on shares of Savara in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright restated a “buy” rating on shares of Savara in a research note on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.